Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMS906 long-term extension in paroxysmal nocturnal hemoglobinuria
ISRCTN73211658Phase 2Recruiting
- Sponsor
- Omeros Corporation
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Omeros Corporation. Primary endpoint: Safety and tolerability. Started Feb 2024; status: recruiting.
02
Drugs
zaltenibart
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on ISRCTN73211658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73211658.